Glaukos Co. (NYSE:GKOS) Stock Position Lowered by D. E. Shaw & Co. Inc.

D. E. Shaw & Co. Inc. lessened its position in Glaukos Co. (NYSE:GKOS) by 99.5% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 2,701 shares of the medical instruments supplier’s stock after selling 495,859 shares during the period. D. E. Shaw & Co. Inc.’s holdings in Glaukos were worth $405,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Rhumbline Advisers raised its stake in shares of Glaukos by 0.3% in the 4th quarter. Rhumbline Advisers now owns 141,790 shares of the medical instruments supplier’s stock worth $21,260,000 after buying an additional 403 shares in the last quarter. IFP Advisors Inc bought a new stake in shares of Glaukos in the 4th quarter worth $43,000. US Bancorp DE raised its stake in shares of Glaukos by 8.3% in the 4th quarter. US Bancorp DE now owns 6,099 shares of the medical instruments supplier’s stock worth $914,000 after buying an additional 470 shares in the last quarter. CIBC Asset Management Inc bought a new stake in shares of Glaukos in the 4th quarter worth $227,000. Finally, Raymond James Financial Inc. bought a new stake in shares of Glaukos in the 4th quarter worth $16,910,000. Institutional investors own 99.04% of the company’s stock.

Insiders Place Their Bets

In other Glaukos news, CFO Alex R. Thurman sold 1,520 shares of the business’s stock in a transaction dated Tuesday, March 25th. The stock was sold at an average price of $106.84, for a total value of $162,396.80. Following the completion of the sale, the chief financial officer now owns 53,431 shares of the company’s stock, valued at $5,708,568.04. The trade was a 2.77% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 5.80% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the company. Stifel Nicolaus dropped their price objective on Glaukos from $140.00 to $115.00 and set a “buy” rating on the stock in a research note on Thursday, May 1st. Piper Sandler decreased their target price on Glaukos from $180.00 to $165.00 and set an “overweight” rating on the stock in a report on Tuesday, April 15th. Mizuho decreased their target price on Glaukos from $200.00 to $175.00 and set an “outperform” rating on the stock in a report on Wednesday, April 16th. Wells Fargo & Company cut Glaukos from an “overweight” rating to an “equal weight” rating and decreased their target price for the stock from $160.00 to $86.00 in a report on Thursday, May 1st. Finally, Truist Financial restated a “buy” rating and issued a $135.00 target price (down from $140.00) on shares of Glaukos in a report on Thursday, May 1st. One investment analyst has rated the stock with a sell rating, two have given a hold rating and ten have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $134.67.

Glaukos Stock Performance

Shares of NYSE GKOS opened at $96.22 on Tuesday. The business’s 50-day moving average price is $93.33 and its two-hundred day moving average price is $124.22. The company has a debt-to-equity ratio of 0.19, a current ratio of 5.54 and a quick ratio of 4.71. Glaukos Co. has a one year low of $77.10 and a one year high of $163.71. The company has a market capitalization of $5.50 billion, a P/E ratio of -33.53 and a beta of 0.83.

Glaukos (NYSE:GKOS) last issued its earnings results on Wednesday, April 30th. The medical instruments supplier reported ($0.22) EPS for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.11. Glaukos had a negative return on equity of 16.53% and a negative net margin of 39.04%. The firm had revenue of $106.66 million for the quarter, compared to the consensus estimate of $102.78 million. During the same quarter in the previous year, the company posted ($0.70) earnings per share. The business’s quarterly revenue was up 24.6% compared to the same quarter last year. Analysts anticipate that Glaukos Co. will post -1.08 earnings per share for the current fiscal year.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.